Fig. 1
Combinatorial drug screening identifies DNA-PKI NU7441 as the top sensitizer for OV M1. a Relative cell viability in 18 tumour cell lines treated with M1 (MOI = 10, 1 or 0.1). For each cell line, the percent cell inhibition is colour-coded by quartile. b A flow diagram of the drug-screening protocol. HCT-116 cells were treated with increasing doses of each compound in the absence or presence of M1 virus (MOI = 1) for 72 h. Then, cell viability was measured by the MTT assay. c Representative compounds for drug screening. Dose–response curves were generated for each drug in the absence or presence of M1 virus, and the DAUC (fold) was calculated according to the formula (AUCSingle−AUCCombined)/AUCCombined; the orange areas represent DAUC. d The agents were ranked according to DAUC (fold) between two dose–response curves for the HCT-116 cell line. Each dot represents one candidate drug from the anticancer compound library. e Top 10 candidate compounds identified through this screening. f IC50 isobolograms of the combined effects of NU7441/M1 in HCT-116 and BxPC-3 cell lines. The x and y axes represent equieffect doses for 50% cell killing by M1 and NU7441, respectively. The observed data points are indicated by the empty triangles
